Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 27299298.
- Also identified by DOI 10.1002/hed.24517.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multifocality of papillary thyroid carcinoma (PTC) is common. BRAF and NRAS mutations are the most frequent genetic alterations in PTC. The purpose of this study was to determine the distribution and relevance of BRAF<sup>T1799A</sup> and NRAS mutations in PTC. BRAF<sup>T1799A</sup> and NRAS mutations were evaluated in 195 intrathyroid or metastatic foci from 29 patients with multifocal PTC. BRAF<sup>T1799A</sup> mutation was positive in 46.7% of the 59 intrathyroid and 136 metastatic foci (91/195 foci). Heterogeneous BRAF pattern was observed in 51.7% patients (15/29 patients). Irrespective of BRAF status at diagnosis (thyroid or nodes), all patients with recurrent PTC presented BRAF-mutated metastases during follow-up. All foci were negative for NRAS mutations. BRAF but not NRAS mutations were heterogeneously distributed among primary tumor, nodal sites, and recurrent disease. The BRAF status of metastases generated during the follow-up can differ from the status of foci at diagnosis. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1772-1779, 2016.
Medical subject headings
- Carcinoma, Papillary
- GTP Phosphohydrolases
- Membrane Proteins
- Mutation
- Neoplasm Recurrence, Local
- Proto-Oncogene Proteins B-raf
- Thyroid Neoplasms